Petrus Trust Company LTA raised its stake in Johnson & Johnson (NYSE:JNJ) by 1.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,541 shares of the company’s stock after acquiring an additional 2,595 shares during the period. Johnson & Johnson makes up about 3.4% of Petrus Trust Company LTA’s portfolio, making the stock its 9th biggest holding. Petrus Trust Company LTA’s holdings in Johnson & Johnson were worth $19,297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Virtus ETF Advisers LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth $25,000. Krane Funds Advisors LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth $26,000. Crewe Advisors LLC grew its position in Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after acquiring an additional 196 shares during the last quarter. Evolution Wealth Advisors LLC bought a new stake in Johnson & Johnson during the 4th quarter worth $40,000. Finally, Permanens Capital L.P. grew its position in Johnson & Johnson by 50.0% during the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after acquiring an additional 100 shares during the last quarter. 72.01% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts recently weighed in on JNJ shares. Raymond James reduced their price objective on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Bank of America restated a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Barclays started coverage on Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 price objective on the stock. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $150.60.
Shares of NYSE JNJ traded down $0.04 during trading on Thursday, reaching $130.37. The company had a trading volume of 210,332 shares, compared to its average volume of 7,507,391. The company’s fifty day moving average price is $130.05 and its 200-day moving average price is $135.78. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The stock has a market cap of $341.88 billion, a P/E ratio of 15.91, a PEG ratio of 2.19 and a beta of 0.68. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the previous year, the company posted $2.10 EPS. The business’s revenue was down 1.3% on a year-over-year basis. As a group, equities analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $0.95 dividend. The ex-dividend date of this dividend was Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.91%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Green Investing
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.